Sotrovimab in controlling SARS-CoV-2 infection
© 2022 MEDPRESS..
The new monoclonal antibodies - VIR -7831 (sotrovimab) and VIR- 7832 - show an action directly targeting the SARS-CoV-2 spike glycoprotein. Moreover, they strongly neutralize in vitro the wild-type Corona virus variants and the omicron variant. Sotrovimab is a monoclonal antibody capable of neutralizing SARS-CoV-2 as well as other sarbecoviruses (SARS-CoV-1 and SARS-CoV). The administration of 500 mg sotrovimab as a 1-hour intravenous infusion in 291 patients with COVID-19 with mild to moderate severity of symptoms prevented disease progression and the need for hospitalization.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:50 |
|---|---|
| Enthalten in: |
Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego - 50(2022), 295 vom: 22. Feb., Seite 48-50 |
| Sprache: |
Polnisch |
|---|
| Weiterer Titel: |
Sotrowimab w kontrolowaniu zakażenia SARS-CoV-2 |
|---|
| Beteiligte Personen: |
Płusa, Tadeusz [VerfasserIn] |
|---|
| Themen: |
1MTK0BPN8V |
|---|
| Anmerkungen: |
Date Completed 15.03.2022 Date Revised 07.12.2022 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM33809069X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM33809069X | ||
| 003 | DE-627 | ||
| 005 | 20231225235902.0 | ||
| 007 | tu | ||
| 008 | 231225s2022 xx ||||| 00| ||pol c | ||
| 028 | 5 | 2 | |a pubmed24n1126.xml |
| 035 | |a (DE-627)NLM33809069X | ||
| 035 | |a (NLM)35278299 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a pol | ||
| 100 | 1 | |a Płusa, Tadeusz |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sotrovimab in controlling SARS-CoV-2 infection |
| 246 | 3 | 3 | |a Sotrowimab w kontrolowaniu zakażenia SARS-CoV-2 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 15.03.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 MEDPRESS. | ||
| 520 | |a The new monoclonal antibodies - VIR -7831 (sotrovimab) and VIR- 7832 - show an action directly targeting the SARS-CoV-2 spike glycoprotein. Moreover, they strongly neutralize in vitro the wild-type Corona virus variants and the omicron variant. Sotrovimab is a monoclonal antibody capable of neutralizing SARS-CoV-2 as well as other sarbecoviruses (SARS-CoV-1 and SARS-CoV). The administration of 500 mg sotrovimab as a 1-hour intravenous infusion in 291 patients with COVID-19 with mild to moderate severity of symptoms prevented disease progression and the need for hospitalization | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a efficacy | |
| 650 | 4 | |a sotrovimab | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Membrane Glycoproteins |2 NLM | |
| 650 | 7 | |a Viral Envelope Proteins |2 NLM | |
| 650 | 7 | |a sotrovimab |2 NLM | |
| 650 | 7 | |a 1MTK0BPN8V |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego |d 1997 |g 50(2022), 295 vom: 22. Feb., Seite 48-50 |w (DE-627)NLM090955315 |x 1426-9686 |7 nnns |
| 773 | 1 | 8 | |g volume:50 |g year:2022 |g number:295 |g day:22 |g month:02 |g pages:48-50 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 50 |j 2022 |e 295 |b 22 |c 02 |h 48-50 | ||